Associated Papers
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Mining of molecular insights of CYP2A6 and its variants complex with coumarin (CYP2A6*-coumarin) using molecular dynamics simulation.
Yadav A et al.
Journal of Biomolecular Structure & Dynamics, 2023
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
Zhou Y et al.
The Pharmacogenomics Journal, 2022
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Variation in CYP2A6 Activity and Personalized Medicine.
Tanner JA et al.
Journal of Personalized Medicine, 2017
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Functional Characterization of 34 CYP2A6 Allelic Variants by Assessment of Nicotine C-Oxidation and Coumarin 7-Hydroxylation Activities.
Hosono H et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2017
Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction.
López-Flores LA et al.
Excli Journal, 2017
A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism.
Loukola A et al.
Plos Genetics, 2015
Inhibitory potency of 8-methoxypsoralen on cytochrome P450 2A6 (CYP2A6) allelic variants CYP2A6 15, CYP2A6 16, CYP2A6 21 and CYP2A6 22: differential susceptibility due to different sequence locations of the mutations.
Tiong KH et al.
Plos One, 2014
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans.
Bloom J et al.
Pharmacogenetics and Genomics, 2011
Functional characterization of cytochrome P450 2A6 allelic variants CYP2A6*15, CYP2A6*16, CYP2A6*21, and CYP2A6*22.
Tiong KH et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2010
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.
di Iulio J et al.
Pharmacogenetics and Genomics, 2009
Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.
Nakajima M et al.
Clinical Pharmacology and Therapeutics, 2006
Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics.
Al Koudsi N et al.
European Journal of Clinical Pharmacology, 2006
Three haplotypes associated with CYP2A6 phenotypes in Caucasians.
Haberl M et al.
Pharmacogenetics and Genomics, 2005
Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation.
Nakajima M et al.
Drug Metabolism and Pharmacokinetics, 2005
Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism.
Oscarson M
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2001